Zika virus vaccine - Protein Sciences Corporation

Drug Profile

Zika virus vaccine - Protein Sciences Corporation

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Protein Sciences Corporation
  • Developer Immunobiological Technology Institute; Laboratorios Liomont; Mundo Sano; National Institute of Allergy and Infectious Diseases; Protein Sciences Corporation; Sinergium Biotech; UMN Pharma
  • Class Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection

Most Recent Events

  • 12 Jan 2017 Protein Sciences and Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz) agree to co-develop Zika virus vaccine in Brazil for Zika virus infection (Prevention)
  • 12 Jan 2017 Early research in Zika virus infection (Prevention) in Brazil (unspecified route)
  • 12 Jan 2017 Early research in Zika virus infection (Prevention) in Mexico (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top